Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 03, 2022

SELL
$144.95 - $152.29 $860,278 - $903,841
-5,935 Reduced 73.13%
2,181 $330,000
Q2 2022

Aug 16, 2022

SELL
$83.14 - $145.99 $928,590 - $1.63 Million
-11,169 Reduced 57.92%
8,116 $1.18 Million
Q1 2022

May 16, 2022

SELL
$110.08 - $142.92 $877,557 - $1.14 Million
-7,972 Reduced 29.25%
19,285 $2.29 Million
Q4 2021

Feb 09, 2022

BUY
$99.73 - $148.48 $635,878 - $946,708
6,376 Added 30.53%
27,257 $3.76 Million
Q3 2021

Nov 12, 2021

BUY
$98.85 - $138.91 $723,384 - $1.02 Million
7,318 Added 53.96%
20,881 $2.9 Million
Q2 2021

Aug 16, 2021

BUY
$65.78 - $105.02 $583,468 - $931,527
8,870 Added 189.0%
13,563 $1.32 Million
Q1 2021

May 14, 2021

BUY
$64.07 - $91.75 $300,680 - $430,582
4,693 New
4,693 $321,000

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $3.18B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.